In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora species
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista Brasileira de Farmacognosia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2019000200241 |
Resumo: | ABSTRACT Hyperuricemia is the main cause of gout, an inflammation induced by uric acid deposition in joints. Drugs available present side effects, so there is a need for new treatment alternatives. Lychnophora species are used in folk medicine to treat inflammation, rheumatism and muscle pain. Goyazensolide (10 mg/kg), eremantholide C (25 mg/kg) and lychnopholide (25 mg/kg), sesquiterpene lactones isolated from Lychnophora species were previously studied and showed anti-hyperuricemic effects in mice. However, the mechanisms of this effect were not elucidated. The methodology of this study consisted in treatment of hyperuricemic-induced rats, and comparison between control groups, clinically used anti-hyperuricemic drugs and sesquiterpene lactones. Urine and blood were collected for uric acid quantification. Xanthine oxidase inhibition was measured in liver homogenates. Results showed that all evaluated sesquiterpene lactones presented anti-hyperuricemic activity at the doses of 5 and 10 mg/kg and can act through one or both mechanisms, depending on the dose administrated. Goyazensolide and lychnopholide at dose of 5 mg/kg showed important uricosuric effect. Goyazensolide and lychnopholide at dose of 10 mg/kg, and eremantholide C (5 and 10 mg/kg) presented notable inhibition of hepatic xanthine oxidase activity and uricosuric effect. Thus, these sesquiterpene lactones are promising hypouricemic agent to treat hyperuricemia and gout. |
id |
SBFGNOSIA-1_d1cfee0dfc374de449fac622221e057d |
---|---|
oai_identifier_str |
oai:scielo:S0102-695X2019000200241 |
network_acronym_str |
SBFGNOSIA-1 |
network_name_str |
Revista Brasileira de Farmacognosia (Online) |
repository_id_str |
|
spelling |
In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora speciesSesquiterpene lactonesHyperuricemiaXanthine oxidaseUricosuric effectGoutABSTRACT Hyperuricemia is the main cause of gout, an inflammation induced by uric acid deposition in joints. Drugs available present side effects, so there is a need for new treatment alternatives. Lychnophora species are used in folk medicine to treat inflammation, rheumatism and muscle pain. Goyazensolide (10 mg/kg), eremantholide C (25 mg/kg) and lychnopholide (25 mg/kg), sesquiterpene lactones isolated from Lychnophora species were previously studied and showed anti-hyperuricemic effects in mice. However, the mechanisms of this effect were not elucidated. The methodology of this study consisted in treatment of hyperuricemic-induced rats, and comparison between control groups, clinically used anti-hyperuricemic drugs and sesquiterpene lactones. Urine and blood were collected for uric acid quantification. Xanthine oxidase inhibition was measured in liver homogenates. Results showed that all evaluated sesquiterpene lactones presented anti-hyperuricemic activity at the doses of 5 and 10 mg/kg and can act through one or both mechanisms, depending on the dose administrated. Goyazensolide and lychnopholide at dose of 5 mg/kg showed important uricosuric effect. Goyazensolide and lychnopholide at dose of 10 mg/kg, and eremantholide C (5 and 10 mg/kg) presented notable inhibition of hepatic xanthine oxidase activity and uricosuric effect. Thus, these sesquiterpene lactones are promising hypouricemic agent to treat hyperuricemia and gout.Sociedade Brasileira de Farmacognosia2019-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2019000200241Revista Brasileira de Farmacognosia v.29 n.2 2019reponame:Revista Brasileira de Farmacognosia (Online)instname:Sociedade Brasileira de Farmacognosia (SBFgnosia)instacron:SBFGNOSIA10.1016/j.bjp.2018.12.008info:eu-repo/semantics/openAccessBernardes,Ana Catharina Fernandes Pereira FerreiraCoelho,Grazielle BrandãoAraújo,Marcela Carolina de Paula MichelSaúde-Guimarães,Dênia Antuneseng2019-05-21T00:00:00Zoai:scielo:S0102-695X2019000200241Revistahttp://www.sbfgnosia.org.br/revista/https://old.scielo.br/oai/scielo-oai.phprbgnosia@ltf.ufpb.br1981-528X0102-695Xopendoar:2019-05-21T00:00Revista Brasileira de Farmacognosia (Online) - Sociedade Brasileira de Farmacognosia (SBFgnosia)false |
dc.title.none.fl_str_mv |
In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora species |
title |
In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora species |
spellingShingle |
In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora species Bernardes,Ana Catharina Fernandes Pereira Ferreira Sesquiterpene lactones Hyperuricemia Xanthine oxidase Uricosuric effect Gout |
title_short |
In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora species |
title_full |
In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora species |
title_fullStr |
In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora species |
title_full_unstemmed |
In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora species |
title_sort |
In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora species |
author |
Bernardes,Ana Catharina Fernandes Pereira Ferreira |
author_facet |
Bernardes,Ana Catharina Fernandes Pereira Ferreira Coelho,Grazielle Brandão Araújo,Marcela Carolina de Paula Michel Saúde-Guimarães,Dênia Antunes |
author_role |
author |
author2 |
Coelho,Grazielle Brandão Araújo,Marcela Carolina de Paula Michel Saúde-Guimarães,Dênia Antunes |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Bernardes,Ana Catharina Fernandes Pereira Ferreira Coelho,Grazielle Brandão Araújo,Marcela Carolina de Paula Michel Saúde-Guimarães,Dênia Antunes |
dc.subject.por.fl_str_mv |
Sesquiterpene lactones Hyperuricemia Xanthine oxidase Uricosuric effect Gout |
topic |
Sesquiterpene lactones Hyperuricemia Xanthine oxidase Uricosuric effect Gout |
description |
ABSTRACT Hyperuricemia is the main cause of gout, an inflammation induced by uric acid deposition in joints. Drugs available present side effects, so there is a need for new treatment alternatives. Lychnophora species are used in folk medicine to treat inflammation, rheumatism and muscle pain. Goyazensolide (10 mg/kg), eremantholide C (25 mg/kg) and lychnopholide (25 mg/kg), sesquiterpene lactones isolated from Lychnophora species were previously studied and showed anti-hyperuricemic effects in mice. However, the mechanisms of this effect were not elucidated. The methodology of this study consisted in treatment of hyperuricemic-induced rats, and comparison between control groups, clinically used anti-hyperuricemic drugs and sesquiterpene lactones. Urine and blood were collected for uric acid quantification. Xanthine oxidase inhibition was measured in liver homogenates. Results showed that all evaluated sesquiterpene lactones presented anti-hyperuricemic activity at the doses of 5 and 10 mg/kg and can act through one or both mechanisms, depending on the dose administrated. Goyazensolide and lychnopholide at dose of 5 mg/kg showed important uricosuric effect. Goyazensolide and lychnopholide at dose of 10 mg/kg, and eremantholide C (5 and 10 mg/kg) presented notable inhibition of hepatic xanthine oxidase activity and uricosuric effect. Thus, these sesquiterpene lactones are promising hypouricemic agent to treat hyperuricemia and gout. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-04-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2019000200241 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2019000200241 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1016/j.bjp.2018.12.008 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Farmacognosia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Farmacognosia |
dc.source.none.fl_str_mv |
Revista Brasileira de Farmacognosia v.29 n.2 2019 reponame:Revista Brasileira de Farmacognosia (Online) instname:Sociedade Brasileira de Farmacognosia (SBFgnosia) instacron:SBFGNOSIA |
instname_str |
Sociedade Brasileira de Farmacognosia (SBFgnosia) |
instacron_str |
SBFGNOSIA |
institution |
SBFGNOSIA |
reponame_str |
Revista Brasileira de Farmacognosia (Online) |
collection |
Revista Brasileira de Farmacognosia (Online) |
repository.name.fl_str_mv |
Revista Brasileira de Farmacognosia (Online) - Sociedade Brasileira de Farmacognosia (SBFgnosia) |
repository.mail.fl_str_mv |
rbgnosia@ltf.ufpb.br |
_version_ |
1752122471126925312 |